You are here: Industry Insights > VLA15

News List

Valneva and Pfizer report further positive Phase 2 data for Lyme disease vaccine candidate WorldPharmaNews
February 07, 2022
Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, and Pfizer Inc. (NYSE: PFE) today reported further positive Phase 2 data for their Lyme disease vaccine candidate, VLA15.
Valneva & Pfizer Report Phase 2 Data for Lyme Disease Vaccine Candidate contractpharma
February 03, 2022
Plan to proceed with a three-dose primary series vaccination schedule in a planned Phase 3 clinical trial.
Valneva fast-tracks paediatric development of Lyme disease vaccine pharmatimes
December 08, 2020
French vaccine specialist Valneva has announced that it will accelerate the paediatric development of its Lyme disease vaccine candidate VLA15, which it is currently developing alongside pharma giant Pfizer.
Valneva bags positive phase II results for Lyme disease vaccine pharmatimes
October 22, 2020
French speciality vaccine company Valneva has announced initial positive results from its second phase II study of its Lyme disease vaccine candidate VLA15.
Valneva Earns $130M Pfizer Milestone in Lyme Vax Pact contractpharma
June 10, 2020
Working to develop and commercialize Valneva’s Lyme disease vaccine candidate VLA15, which is currently in Phase II clinical studies.
Valneva and Pfizer collaborate for Lyme disease vaccine expresspharma
May 04, 2020
VLA15 is the only active Lyme disease vaccine programme in clinical development today, and covers six serotypes that are prevalent in North America and Europe.